Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer disease in subjects with Down syndrome

dc.contributor.author
Carmona-Iragui, Maria
dc.contributor.author
Santos, Telma
dc.contributor.author
Videla, Sebastià
dc.contributor.author
Fernández, Susana
dc.contributor.author
Benejam, Bessy
dc.contributor.author
Videla, Laura
dc.contributor.author
Alcolea, Daniel
dc.contributor.author
Blennow, Kaj
dc.contributor.author
Blesa González, Rafael
dc.contributor.author
Lleo, Alberto
dc.contributor.author
Fortea Ormaechea, Juan
dc.date.issued
2020-12-18T16:51:47Z
dc.date.issued
2020-12-18T16:51:47Z
dc.date.issued
2017-10-01
dc.date.issued
2020-12-18T16:51:47Z
dc.identifier
1387-2877
dc.identifier
https://hdl.handle.net/2445/172764
dc.identifier
697988
dc.identifier
27858714
dc.description.abstract
Background: Alzheimer's disease (AD) is the main medical problem in older adults with Down syndrome (DS). Studies of cerebrospinal fluid (CSF) AD biomarkers are limited and the feasibility of lumbar puncture (LP) is controversial in this population. Objective: to analyze the frequency of complications after a LP in DS. Methods: we collected data from 80 adults with DS that underwent a LP within the Down Alzheimer Barcelona Neuroimaging Initiative. Demographics, cognitive status, headache history, and presence of complications after the LP were recorded in every subject. In 53 of them (active group), this information was collected following a semi-structured and validated protocol that actively looks for complications. Other variables related to the LP procedure were also recorded. A telephone interview to the caregiver was performed 5-7 days after the procedure to ask about complications. Data from 27 subjects (clinical practice group), from whom the presence of complications was obtained in a medical follow-up visit within the three months after the LP, were also included. Results: there were no adverse events in 90% of our participants. The most frequent complication was headache (6.25%); only one subject reported a typical post-lumbar puncture headache with moderate severity that required analgesic treatment. Dizziness (3.75%) and back pain (1.25%) were also reported. All the participants that reported complications belonged to the active group. Conclusion: LP can be safely performed to study CSF biomarkers in DS. The reported complications are qualitatively similar to the general population, but are less frequently reported, even when actively searched for.
dc.format
8 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
IOS Press
dc.relation
Reproducció del document publicat a: https://doi.org/10.3233/JAD-160827
dc.relation
Journal of Alzheimer's Disease, 2017, vol. 55, num. 4, p. 1489-1496
dc.relation
https://doi.org/10.3233/JAD-160827
dc.rights
(c) Carmona-Iragui, Maria et al., 2017
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Líquid cefalorraquidi
dc.subject
Malaltia d'Alzheimer
dc.subject
Síndrome de Down
dc.subject
Punció lumbar
dc.subject
Cerebrospinal fluid
dc.subject
Alzheimer's disease
dc.subject
Down syndrome
dc.subject
Spinal puncture
dc.title
Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer disease in subjects with Down syndrome
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)